Cargando…
Author Correction: Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033276/ https://www.ncbi.nlm.nih.gov/pubmed/32080316 http://dx.doi.org/10.1038/s41598-020-60644-9 |
| _version_ | 1783499630903820288 |
|---|---|
| author | Morimoto, Takeshi Sakuma, Ichiro Sakuma, Mio Tokushige, Akihiro Natsuaki, Masahiro Asahi, Tomohiro Shimabukuro, Michio Nomiyama, Takashi Arasaki, Osamu Node, Koichi Ueda, Shinichiro |
| author_facet | Morimoto, Takeshi Sakuma, Ichiro Sakuma, Mio Tokushige, Akihiro Natsuaki, Masahiro Asahi, Tomohiro Shimabukuro, Michio Nomiyama, Takashi Arasaki, Osamu Node, Koichi Ueda, Shinichiro |
| author_sort | Morimoto, Takeshi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7033276 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-70332762020-02-28 Author Correction: Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial Morimoto, Takeshi Sakuma, Ichiro Sakuma, Mio Tokushige, Akihiro Natsuaki, Masahiro Asahi, Tomohiro Shimabukuro, Michio Nomiyama, Takashi Arasaki, Osamu Node, Koichi Ueda, Shinichiro Sci Rep Author Correction Nature Publishing Group UK 2020-02-21 /pmc/articles/PMC7033276/ /pubmed/32080316 http://dx.doi.org/10.1038/s41598-020-60644-9 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Author Correction Morimoto, Takeshi Sakuma, Ichiro Sakuma, Mio Tokushige, Akihiro Natsuaki, Masahiro Asahi, Tomohiro Shimabukuro, Michio Nomiyama, Takashi Arasaki, Osamu Node, Koichi Ueda, Shinichiro Author Correction: Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial |
| title | Author Correction: Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial |
| title_full | Author Correction: Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial |
| title_fullStr | Author Correction: Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial |
| title_full_unstemmed | Author Correction: Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial |
| title_short | Author Correction: Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial |
| title_sort | author correction: randomized evaluation of anagliptin vs sitagliptin on low-density lipoprotein cholesterol in diabetes (reason) trial: a 52-week, open-label, randomized clinical trial |
| topic | Author Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033276/ https://www.ncbi.nlm.nih.gov/pubmed/32080316 http://dx.doi.org/10.1038/s41598-020-60644-9 |
| work_keys_str_mv | AT morimototakeshi authorcorrectionrandomizedevaluationofanagliptinvssitagliptinonlowdensitylipoproteincholesterolindiabetesreasontriala52weekopenlabelrandomizedclinicaltrial AT sakumaichiro authorcorrectionrandomizedevaluationofanagliptinvssitagliptinonlowdensitylipoproteincholesterolindiabetesreasontriala52weekopenlabelrandomizedclinicaltrial AT sakumamio authorcorrectionrandomizedevaluationofanagliptinvssitagliptinonlowdensitylipoproteincholesterolindiabetesreasontriala52weekopenlabelrandomizedclinicaltrial AT tokushigeakihiro authorcorrectionrandomizedevaluationofanagliptinvssitagliptinonlowdensitylipoproteincholesterolindiabetesreasontriala52weekopenlabelrandomizedclinicaltrial AT natsuakimasahiro authorcorrectionrandomizedevaluationofanagliptinvssitagliptinonlowdensitylipoproteincholesterolindiabetesreasontriala52weekopenlabelrandomizedclinicaltrial AT asahitomohiro authorcorrectionrandomizedevaluationofanagliptinvssitagliptinonlowdensitylipoproteincholesterolindiabetesreasontriala52weekopenlabelrandomizedclinicaltrial AT shimabukuromichio authorcorrectionrandomizedevaluationofanagliptinvssitagliptinonlowdensitylipoproteincholesterolindiabetesreasontriala52weekopenlabelrandomizedclinicaltrial AT nomiyamatakashi authorcorrectionrandomizedevaluationofanagliptinvssitagliptinonlowdensitylipoproteincholesterolindiabetesreasontriala52weekopenlabelrandomizedclinicaltrial AT arasakiosamu authorcorrectionrandomizedevaluationofanagliptinvssitagliptinonlowdensitylipoproteincholesterolindiabetesreasontriala52weekopenlabelrandomizedclinicaltrial AT nodekoichi authorcorrectionrandomizedevaluationofanagliptinvssitagliptinonlowdensitylipoproteincholesterolindiabetesreasontriala52weekopenlabelrandomizedclinicaltrial AT uedashinichiro authorcorrectionrandomizedevaluationofanagliptinvssitagliptinonlowdensitylipoproteincholesterolindiabetesreasontriala52weekopenlabelrandomizedclinicaltrial |